Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An open-label assessment of TMC 125--a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance.

AIDS (London, England) - 5 Dec 2003

Gazzard Brian G, Pozniak Anton L, Rosenbaum Willy, Yeni G Patrick, Staszewski Schlomo, Arasteh Keikawus, De Dier Karin, Peeters Monika, Woodfall Brian, Stebbing Justin, vant' Klooster Gerben A

Abstract excerpt

UNLABELLED: The development of resistance to any of the currently licensed non-nucleoside reverse transcriptase inhibitors (NNRTI) invariably leads to cross-resistance to the drugs in that class. New NNRTI, that have the promise of being active even when such 'signature' mutations are present, are in development. Such novel therapies could be effective after current NNRTI failure as there would probably be no...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Viral
Share to HIV-1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Infections

Share to Nitriles

Share to Pyridazines

Share to Pyrimidines

Share to Reverse Transcriptase Inhibitors

Share to Viral Load

Source

Identifiers

PMID: 14685068
DOI: 10.1097/00002030-200312050-00001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An open-label assessment of TMC 125--a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance.PMID 14685068Read ↗

TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.Semantic proximity Read ↗

Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors.Semantic proximity Read ↗

Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis.Semantic proximity Read ↗

TMC 125 possibly effective against NNRTI-resistant HIV.Semantic proximity Read ↗

A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects.Semantic proximity Read ↗

Resistance and cross-resistance profile of the diaryltriazine NNRTI and candidate microbicide UAMC01398.Semantic proximity Read ↗

TMC125 Displays a High Genetic Barrier to the Development of Resistance: Evidence from In Vitro Selection ExperimentsSemantic proximity Read ↗

Clinical Utility of Current NNRTIs and Perspectives of New Agents in This Class under DevelopmentSemantic proximity Read ↗

TMC125 study highlights failing NNRTI regimen task.Semantic proximity Read ↗

A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integraseSemantic proximity Read ↗

Safety and efficacy of GSK2248761, a next-generation nonnucleoside reverse transcriptase inhibitor, in treatment-naive HIV-1-infected subjects.Semantic proximity Read ↗

Antiviral Activity of MK-4965, a Novel Nonnucleoside Reverse Transcriptase InhibitorSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.